Niagen (NAGE) Q3 2026 Earnings Call Transcript

Niagen Bioscience reported Q3 2026 net sales of $27.2 million, down 20% year over year, and a $1.2 million net loss versus $4.6 million net income a year earlier; adjusted EBITDA fell to $455,000 from $6.4 million. Gross margin declined 160 basis points to 62.9%, while website sales grew 13% (17% adjusted for Prime Day timing), and the company generated $2.6 million in operating cash flow with $69.5 million in cash and no debt. Management expects Q4 revenue to improve sequentially and projects full-year website revenue growth of 15%–20% and e-commerce growth of about 5%, while describing 2026 as an investment year ahead of targeted 2027 growth.

Analysis

Near term, the key issue is not solvency but operating leverage: weaker sales and mix have pushed marketing spend to a larger share of revenue, while management plans further investment. If channel growth fails to convert into consolidated sales, earnings could remain pressured even as the company reports positive cash flow. DTC strength is a useful counter-signal, but it does not yet establish that new retail, clinic, and product channels can scale profitably; channel-level sales and customer-acquisition payback are missing.

Over 1–3 months, watch Q4 order conversion and whether sequential improvement arrives without further gross-margin erosion. The ingredient business’s exposure to a large customer and NMN price competition makes order timing a genuine volatility source. Over 6–18 months, lower-cost NR malate could improve competitiveness, but qualification, regulatory acceptance by market, and realized cost savings—not management’s estimate—are the proof points. The prevention trial and NB4168 offer long-dated optionality, not a near-term earnings floor; trial duration, development costs, and regulatory outcomes remain uncertain. The favorable court ruling described addresses an attorney-fee award and remand request; it should not be treated as resolution of the broader patent or NMN disputes.

Contrarian balance: the commercial deceleration is concerning, but debt-free liquidity limits financing risk and gives NAGE time to execute. That also weakens the case for an aggressive short; current evidence supports caution rather than a high-conviction directional bet. No clear read-through to Evotec SE (EVO): its cited role in development work does not establish material revenue or earnings sensitivity.

Key Decisions for Investors

• Keep NAGE underweight versus a broad healthcare or consumer-staples benchmark until reported sales stabilize and gross margin stops contracting; avoid adding solely on the long-dated pipeline narrative.
• Use the next results as a trigger: reassess if sequential sales improvement is confirmed and DTC growth translates into consolidated growth without a higher marketing burden. Falsification of the cautious thesis would be sustained revenue recovery plus stable or improving gross margin.
• Track NR malate commercialization as a conditional catalyst, not an earnings assumption. Verify ingredient qualification, regulatory status by target market, customer adoption, and reported cost-of-goods impact before underwriting margin upside.
• Monitor cash generation against planned trial, commercialization, and legal spending. A sustained deterioration in operating cash flow or a material increase in spending without sales traction would strengthen the downside case; current liquidity makes near-term dilution risk less central.